Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 152   

Articles published

NVS 98.34 -0.19 (-0.19%)
price chart
Novartis AG (ADR) (NVS) To Acquire Spinifex
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million  Bidness ETC
Novartis to buy privately held Spinifex for $200 mln  Proactive Investors USA & Canada
Novartis AG (ADR) Says Cosentyx Can Be A $5 Billion Drug After New Trial Data
Novartis AG (ADR) (NYSE:NVS) has updated its annual sales forecast for its potential blockbuster injectable drug Cosentyx (secukinumab), after new clinical data establishes the drug's long-term benefits in treating psoriatic arthritis.
Stock Report on Novartis AG (ADR) (NYSE:NVS)
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Technical Insights on Novartis AG (ADR) (NYSE:NVS)
[Bloomberg] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) the world's biggest drugmaker by sales, reported first-quarter profit that beat analysts' estimates as the company begins to benefit from a set of transactions that make it smaller and more ...
Novartis AG (ADR) (NVS) Seeks $2-5 Billion Takeover Targets  Bidness ETC
Novartis (NVS) Beats on Earnings in Q1, View Reiterated  Zacks.com
General Report on Novartis AG (ADR) (NYSE:NVS)
[Reuters] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S.
Novartis AG (ADR) Partners With Aduro Biotech With A $750 Million Deal
Novartis AG (ADR) (NYSE:NVS) has announced a deal with cancer immunotherapy company, Aduro Biotech, Inc., in which both the companies will partner to research and manufacture treatments for cancer.
Novartis AG (ADR) Inks $750 Million Deal With Aduro Biotech  Bidness ETC
Novartis AG (ADR) (NYSE:NVS) is All Set to Rule the Immunotherapy Market
Head of Novartis AG (ADR) (NYSE:NVS)'s oncology department Mr. Bill Hinshaw, said in one of his recent webcast briefing that Novartis will be playing an important role in this field and the company is well-positioned to do so.
Pre-Market Stocks Roundup: Novartis AG (ADR) (NYSE:NVS), Rackspace ...
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and ...
Stock To Watch : Novartis AG (ADR)(NYSE:NVS)
Novartis AG (ADR)(NYSE:NVS) (TREND ANALYSIS) shares are still trading near the 52-week high of $102.59. The stock closed last trading session at $101.48, with a volume of 1,334,174 shares against an average volume for the last 3 months of 1,498,780.
Novartis AG (ADR) Expects Higher Profit Margin & Dividends This Year
Novartis AG (ADR) (NYSE:NVS) expects its profit margin to increase in 2015 on the back of a restructured drug portfolio and cost-cutting measures.